coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

Subjects

Subjects :

Oncology
medicine.medical_specialty
Pathology
Metastatic melanoma
endocrine system diseases
Placebo-controlled study
Locally advanced
General Biochemistry, Genetics and Molecular Biology
Double blind
chemistry.chemical_compound
Internal medicine
medicine
Vemurafenib
skin and connective tissue diseases
neoplasms
Cobimetinib
Medicine(all)
business.industry
Biochemistry, Genetics and Molecular Biology(all)
General Medicine
digestive system diseases
enzymes and coenzymes (carbohydrates)
chemistry
Oral Presentation
business
medicine.drug

Details

Language :

English

ISSN :

14795876

Volume :

13

Issue :

Suppl 1

Database :

OpenAIRE

Journal :

Journal of Translational Medicine

Accession number :

edsair.doi.dedup.....24feeaff70cb1c07098bd5df37b238fe

Full Text :

https://doi.org/10.1186/1479-5876-13-s1-o4